Levetiracetam (LEV) is a new antiepileptic drug with a promising preclinical profile involving both anticonvulsant and antiepileptogenic effects in kindling models. The latter stimulated the present study to compare its neuroprotective properties with the potent and selective, non-competitive NMDA antagonist, MK-801, in the rat middle cerebral artery occlusion model. Twentyfour hours after a transient occlusion of 90 minutes the animals were sacrificed and infarct volume and lesion distribution were determined from stained coronal sections. LEV was administered by intraperitoneal (i.p.) bolus injections of 5.5, 11, 22 and 44 mg kg −1 , 30 minutes before occlusion followed by a continuous 24 hour i.p. infusion of 1.25, 2.6, 5.1 and 10.2 mg kg −1 per hour, respectively. LEV administration did not alter body temperature but reduced the infarct volume by 33% (P< 0.05) at the highest dose tested. An i.p. bolus injection of 0.04, 0.12 and 0.4 mg kg −1 of MK-801 followed by continuous i.p. infusion of 0.036, 0.108 and 0.36 mg kg −1 per hour, reduced the infarct volume by 49, 51 and 74% (P< 0.05), respectively. However, only the highest dose of MK-801 induced a significant reduction in the infarct volume (P< 0.05) and this was associated with hypothermia. These results suggest that LEV possesses neuroprotective properties which may be relevant for its antiepileptogenic action.
INTRODUCTION
Levetiracetam (LEV) is a new antiepileptic drug with a promising preclinical profile 1 . Previous studies suggest that LEV provides seizure protection in various animal seizure models and displays a favourable safety margin [1] [2] [3] . Furthermore, it has recently been demonstrated that LEV produces antiepileptogenic effects in an animal kindling model during kindling development at doses which are devoid of sedative and ataxiogenic adverse effects 4 . This contrasts with established antiepileptic drugs (AEDs) of which only valproate and, to a lesser extent, phenobarbital reveal antiepileptogenic effects, but only at high doses associated with severe adverse effects 5 . These results suggest that LEV might not only be a novel drug for the symptomatic treatment of epilepsy, but also for the pharmacological prevention of this disease.
The most common neuropathological finding in temporal lobe epilepsy (TLE) is mesial temporal sclerosis, which primarily affects the hippocampus and other limbic structures 6 . Observations in animal models of epilepsy, as well as in human epilepsy, suggest that TLE involves a substantial neuronal loss and an associated axonal reorganization (mossy fibre sprouting) which may induce the epileptogenic condition 7 . This suggests that drugs preventing neuronal death may counteract the epileptogenic process, although the precise mechanisms by which the hippocampus and other limbic structures generate epileptic discharges in TLE remains to be elucidated. Studies in animals have shown a potent action of NMDA antagonists against both neuronal death associated with cerebral ischemia 8 as well as antiepileptogenic effects against kindling development 9 . This supports a correlation between neuronal death and epileptogenesis 7 . Thus, the antiepileptogenic properties of LEV in the kindling model prompted us to study its potential neuroprotective properties against experimental ischemia in rodents. For comparison, we also evaluated the effect of the non-competitive NMDA antagonist, MK-801.
MATERIALS AND METHODS

Animals
Adult male rats (Wistar) weighing 300-350 g were used. The animals were fed ad libitum and were maintained on a 12 hour light/dark cycle. All animals were weighed before surgery and 24 hours later, before being killed.
Middle cerebral artery occlusion
Transient focal ischemia was induced by the intraluminal suture method 10 , modified from that originally described by Koizumi 11 .
Anaesthesia was induced with a gaseous mixture of 2% isoflurane in N 2 O + O 2 (70/30 V/V) for ≈5 minutes and maintained with a 0.5% mixture delivered through a face mask (unassisted respiration). Atropine, 0.4 mg kg −1 , was injected intraperitoneally (i.p.) to prevent oversecretion of the respiratory tract. During surgery, the animals were kept on a heating pad (at 33-34 • C) and covered with a small blanket in order to maintain body (rectal) temperature between 37 and 38 • C. The rectal temperature was continuously monitored with a rectal probe inserted to a 4 cm depth from the anal ring.
A nylon monofilament (number 0.25 from Platil, Western Germany) was used for the intraluminal occluder. One extremity was rounded and polished with metalographic carborandum-coated paper (grains of 13 µm). The filaments were heated to 50 • C in a water bath, immediately prior to use, in order to increase the flexibility and to avoid perforations during introduction. The diameter of the filaments was measured with electronic callipers and those filaments exceeding the range of 270-290 µm were rejected. The carotid bifurcation was exposed through a ventral midline incision of the neck and the common and external carotid arteries were ligated with a 3-0 silk suture. The pterygopalatine artery was occluded with a u-shaped silver microclip (1 mm wide) lighty pressed around the artery and a 3-0 silk suture placed around the internal carotid, 1 mm distal from the bifurcation, but kept loose until the occluder was fully introduced. The intraluminal occluder was introduced in the internal carotid through an arteriectomy near the bifurcation of the carotid. The length of filament introduced in the carotid and Willis polygon was between 18 and 18.5 mm. The suture around the internal carotid and the filament was tightened when the filament was in the correct position.
An osmotic mini-pump was implanted laterally under the abdominal skin and connected to a catheter (PE50 polyethylene) opening in the peritoneal cavity in order to infuse treatments over 24 hours. After completion of the surgery, the anaesthesia was terminated, and the animals were allowed to recover in individually thermoregulated cages. If necessary, the temperature of this cage was lowered by up to 6-10 • C in order to maintain the body temperature of animals between 36 and 38 • C and to avoid hyperthermia induced by MCA obstruction. To allow reperfusion in the MCA territory, the filament was gently retracted (≈10 mm length) 90 minutes after its insertion, under a short 2% isoflurane anaesthesia. The animals were maintained for 1 hour in the thermoregulated cages before being returned to their home cage. Rectal temperature of the rats subjected to occlusion was measured at the beginning and at the end of the surgery, 60 minutes after occlusion, at the end of the occlusion and 24 hours after surgery (immediately before sacrifice).
Twenty-four hours later, the animals were deeply anaesthetized with isofurane 2% and decapitated. Blood samples were taken by puncture of the abdominal vena cava in order to measure plasma levels of LEV. The brains were quickly removed and rapidly cooled in melting ice for 5 minutes. The brains were immediately sliced at 4 • C with a vibratome into 2 mm coronal sections. Coronal slices were incubated for 10 minutes at 36-36.5 • C in a solution of 1% triphenyltetrazolium chloride (TTC, Sigma Chemical Co.), buffered at pH 7.1 with Na 2 HPO 4 . Staining was stopped by plunging the slices into melting ice. The first slice was at a distance of 3 mm from the frontal pole. The slices were photographed with a 3CCD camera and digitized. The green component of the colour (rgb) picture was used to measure the total area and the unstained area of the slice. The slice was divided into a right and a left side.
The infarct area was calculated as the difference between the right unstained area minus the left unstained area. The total infarct volume was calculated as the sum of the infarct areas from the frontal pole through all the five slices, assuming a thickness of 2 mm. The amount of ischemic damage was expressed in cubic millimetres.
Frequency maps of lesions were computergenerated by adding, on a pixel basis, the pictures of coronal slices cut at the same level. Prior to addition, the digital pictures were split into their red, green and blue components. Only the green picture was used. A cluster analysis was performed to split the population of pixels into two sub-populations on the basis of their green intensity. A binary picture was generated at the end of this operation. The pictures were then centred and rotated in order to match each other. The binary pictures were added to each other and divided by the total number of pictures in each group in order to obtain a value for each individual pixel, which was representative of the number of animals lesioned at each location. The frequency was colour coded to increase the legibility of the maps.
Drugs
LEV and (+)-MK-801 (RBI) were dissolved in saline. Control groups received the vehicle only. MK-801 was injected i.p., 30 minutes before occlusion, at doses of 0.04, 0.12 or 0.40 mg kg −1 followed by continuous infusion (24 hours) of 0.036, 0.108, 0.360 mg kg −1 per hour, respectively 12 . LEV was administered i.p., 30 minutes before occlusion, at doses of 5.5, 11, 22 and 44 mg kg −1 followed by continuous infusion (24 hours) of 1.25, 2.6, 5.1 and 10.2 mg kg −1 per hour, respectively. All the osmotic mini-pumps were primed by a 3-hour immersion in saline at 37 • C in order to flow immediately when implanted.
Data analysis and statistics
Body temperature and plasma levels of LEV are expressed as means ± SD and infarct volumes as medians with first and third quartiles. Infarct volumes were compared with a Kruskal-Wallis test followed by a non-parametric test corrected for multiple comparisons vs. the control group 13 . The relationship between administered doses and infarct volume was evaluated by a linear trend test on ranks 14 . Body temperatures were compared using a one-way analysis of variance followed by a Dunnett's test. Animals displaying cerebral hematoma at necropsy were discarded from the statistical analysis. The hematoma were most due to a likely haemorrhage resulting from the introduction of the occluder. These hematoma were unrelated to the drug treatment.
Ethical approval
The protocol of middle cerebral artery occlusion was approved by the local Ethics Committee for laboratory animals according to Belgian law.
RESULTS
Plasma levels of levetiracetam
The lowest dose of LEV (i.p. bolus 5.5 mg kg −1 + i.p. infusion 1.25 mg kg −1 per hour) resulted in plasma levels of 6.5 ± 0.5 µg ml −1 (n = 9) 24 hours after onset of the infusion. At the same time point, the doses of 11, 22 and 44 mg kg −1 followed by infusions of 2.6, 5.1, and 10.2 mg kg −1 per hour resulted in plasma levels of 12.8 ± 1.5 (n = 7), 28.1 ± 7.6 (n = 8) and 58 ± 15 µg ml −1 (n = 8). This appears within the range of the plasma concentrations obtained in epilepsy patients. Thus, a metaanalysis on data obtained in the four phase III studies performed so far with adjunctive therapy of LEV in adults with refractory partial epilepsy revealed trough plasma levels of between 6 and 17 µg ml −1 and C 1 hour (close to C max ) values between 15 and 43 µg ml −1 (unpublished results of UCB Pharma).
Body temperature
Occlusion of MCA increased body temperature by 0.5-1.5 • C during the occlusion and the following hours, but 24 hours after occlusion the temperature had returned to baseline (Table 1) . Treatment with LEV did not alter body temperature, whereas the highest dose of MK-801 (0.4 mg kg −1 ) significantly reduced the temperature increase (Table 1) .
Infarct volume
Transient MCA occlusion in the vehicle-treated rats of the LEV and MK-801 control groups resulted in infarct lesions of 209 mm 3 (179-231) and 211 mm 3 (116-252), respectively (Figs 1(a) and 1(b) ).
LEV administration reduced the infarct volume ( Fig. 1(a) ). With a dose of 11 mg kg −1 , the median infarct volume was 149 mm 3 (106-203) (P< 0.05), at a dose of 22 mg kg −1 the volume was 155 mm 3 (144-197) , and at the highest tested dose, 44 mg kg −1 , the volume was 140 mm 3 (108-191) (P< 0.05). The latter reflects a reduction of 33%. In contrast, no major effects were observed with the lowest dose of 5.5 mg kg −1 . The linear trend test indicated that the dose range used induced a progressive reduction in the infarct volume (P< 0.05).
MK-801 administration also reduced the infarct volume ( Fig. 1(b) ). At a dose of 0.04 mg kg −1 , the median infarct volume was 108 mm 3 (92-223), at 0.12 mg kg −1 , the volume was 107 mm 3 (77-254 ) and at the highest tested dose, 0.40 mg kg −1 , the volume was 54 mm 3 (10-189) (P< 0.05). This represents re- ductions of 49, 51 and 74%, respectively. However, despite these important reductions in the infarct volume it should be noted that only the highest dose of MK-801 induced a significant effect. This relates to a response in both the control as well as the MK-801 treated groups which were more heterogenous than in the experiment with LEV (Fig. 1) . Furthermore, the group sizes were also small for the experiment with MK-801 compared with that for LEV ( Table 1) . The linear trend test indicated that the dose range used induced a progressive reduction in the infarct volume (P< 0.05).
Frequency maps of lesion distribution
Frequency maps indicate that the infarct occurred in the caudate putamen and in the dorso-lateral and ventral cortex (Fig. 2) . The corpus callosum could not be differentiated from the infarct region due to its low content of mitochondria, which abolishes a reaction with TTC. In preliminary experiments, we observed that increasing the duration of the occlusion from 30 to 120 minutes induced a progression of the lesion from the caudate putamen to the cortex (data not shown). These cortical regions appeared to be rescued from necrosis due to treatment with LEV (Fig. 2) . In general, MK-801 exerted its effect in the same cortical regions, but at the highest dose (which produced hypothermia), a more generalized effect was observed which included the caudate putamen region (Fig. 2) .
DISCUSSION
Experiments with models of focal ischemia in several species have consistently shown that administration of NMDA antagonists both before and after ischemia reduce the infarct size, whereas there are more conflicting reports from models of global ischemia 15 . The present study confirms that preadministration of MK-801 can reduce the infarct size induced by a middle cerebral artery occlusion in rats. Indeed, our findings of a reduction in infarct volume of between 45 and 72% corroborate previous reports showing a decrease varying between 15 and 73% 8 . This supports the validity of our experimental conditions. Body (and cerebral) temperature constitute an important physiological variable in neuroprotection studies and there is substantial evidence that hypothermia confers neuroprotection 16 . Indeed, it has been reported that MK-801 failed to protect against global ischemia if the animals were prevented from becoming hypothermic after dosing 17 . Although this notion can be questioned for focal ischemia, where NMDA receptor antagonists have been shown to be very effective even under conditions of strict temperature regulation 18 , it is clear that hypothermic effects may enhance the neuroprotection observed after dosing with MK-801. This appears to be confirmed by the results of the present study in which only the highest hypothermic dose of MK-801 induced a significant reduction in the infarct volume.
Clinical studies with NMDA antagonists in both stroke 15 and epilepsy patients 19 have revealed a high incidence of adverse effects including confusion, impaired concentration, agitation and hallucinations. So far, this has hampered the clinical utility of this class of compounds. The antiepileptogenic effects observed in the rat amygdala-kindling model with LEV during kindling acquisition 4 were obtained with chronic administration of doses similar to those used in the present study. Furthermore, neuroprotective effects in acute ischemia models have previously been observed both with the established AEDs valproate and phenobarbital 20 and the newer AEDs tiagabine 21 and lamotrigine 22 , all known to possess antiepileptogenic properties in kindling models (see below). Together with previous reports 7 this supports the finding that the neuroprotective properties of LEV may be relevant to its antiepileptogenic action.
All established AEDs demonstrate marked anticonvulsant effects in kindling models (i.e. inhibition of seizures evoked in fully kindled animals), but only valproate and phenobarbital exert antiepileptogenic properties in these models (i.e. inhibition of kindling development) 15, 23 . Among the newer AEDs, tiagabine 24 , vigabatrin 25 and lamotrigine 26 also reveal antiepileptogenic effects in kindling models. In contrast, NMDA antagonists lack significant anticonvulsant effects, but show a potent antiepileptogenic action in kindling models 9, 27 . LEV demonstrates a dual action in the kindling paradigm, incorporating both anticonvulsant effects in fully kindled animals, and antiepileptogenic effects during kindling acquisition 3, 4 . Thus, LEV appears to possess novel properties which distinguish it from traditional anticonvulsant agents. The results of the present study suggest that this may be related to the neuroprotective effects displayed by LEV.
In summary, the present study demonstrates that LEV induces significant neuroprotection in a rat model of focal cerebral ischemia. This effect was correlated with plasma levels comparable both to those inducing antiepileptogenic effects against kindling development in rats and to those inducing anticonvulsant effects in epilepsy patients. In line with previous reports 7 , these results suggest that the neuroprotective properties of LEV may be relevant to its antiepileptogenic action.
